[go: up one dir, main page]

SI2024341T1 - Novi postopek za statine in njihove farmacevtsko sprejemljive soli - Google Patents

Novi postopek za statine in njihove farmacevtsko sprejemljive soli

Info

Publication number
SI2024341T1
SI2024341T1 SI200731752T SI200731752T SI2024341T1 SI 2024341 T1 SI2024341 T1 SI 2024341T1 SI 200731752 T SI200731752 T SI 200731752T SI 200731752 T SI200731752 T SI 200731752T SI 2024341 T1 SI2024341 T1 SI 2024341T1
Authority
SI
Slovenia
Prior art keywords
statins
pharmaceutically acceptable
acceptable salts
novel process
novel
Prior art date
Application number
SI200731752T
Other languages
English (en)
Inventor
Reddy Manne Satyanarayana
Rajan Srinivasan Thirumalai
Reddy Maramreddy Sahadeva
Original Assignee
Msn Laboratories Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msn Laboratories Private Limited filed Critical Msn Laboratories Private Limited
Publication of SI2024341T1 publication Critical patent/SI2024341T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/28—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/28—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/283—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by hydrogenation of unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/28—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/29—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by introduction of oxygen-containing functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/31—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200731752T 2006-05-03 2007-04-30 Novi postopek za statine in njihove farmacevtsko sprejemljive soli SI2024341T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN805CH2006 2006-05-03
IN606CH2007 2007-03-26
EP07736602.9A EP2024341B1 (en) 2006-05-03 2007-04-30 Novel process for statins and its pharmaceutically acceptable salts thereof
PCT/IN2007/000172 WO2007125547A2 (en) 2006-05-03 2007-04-30 Novel process for statins and its pharmaceutically acceptable salts thereof

Publications (1)

Publication Number Publication Date
SI2024341T1 true SI2024341T1 (sl) 2016-04-29

Family

ID=38655913

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731752T SI2024341T1 (sl) 2006-05-03 2007-04-30 Novi postopek za statine in njihove farmacevtsko sprejemljive soli

Country Status (6)

Country Link
US (1) US8455640B2 (sl)
EP (1) EP2024341B1 (sl)
ES (1) ES2564250T3 (sl)
HU (1) HUE027872T2 (sl)
SI (1) SI2024341T1 (sl)
WO (1) WO2007125547A2 (sl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2564250T3 (es) 2006-05-03 2016-03-21 Msn Laboratories Private Limited Nuevo proceso para estatinas y sus sales farmacéuticamente aceptables de las mismas
EP1948618A1 (en) 2006-09-18 2008-07-30 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin calcium
EP2086945B1 (en) * 2006-10-09 2016-01-06 MSN Laboratories Private Limited Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
US20100069635A1 (en) * 2006-11-29 2010-03-18 Dr. Reddy's Laboratories Ltd. Rosuvastatin dehydroabietylamine salt
WO2010023678A1 (en) * 2008-08-27 2010-03-04 Biocon Limited A process for preparation of rosuvastatin intermediate
EP2334667A4 (en) * 2008-09-09 2011-10-26 Biocon Ltd PROCESS FOR THE PREPARATION OF ACETONIDE ROSUVASTATIN CALCIUM
WO2010077062A2 (en) * 2008-12-29 2010-07-08 Hanmi Pharm. Co., Ltd. Preparation method of statin compound and benzothiazolyl sulfone compound used therein
EP2752407B1 (en) * 2009-01-14 2015-09-23 Krka Tovarna Zdravil, D.D., Novo Mesto Crystalline rosuvastatin calcium trihydrate
AU2010205464A1 (en) * 2009-01-15 2011-08-18 Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag Process for the preparation of rosuvastatin salts
EP2387561A4 (en) 2009-01-19 2012-07-25 Msn Lab Ltd IMPROVED PROCESS FOR THE PREPARATION OF HIGH-PURITY (3R, 5S) -7-β-CYCLOPROPYL-4- (4-FLUOROPHENYL) QUINOLIN-3-YL-3,5-DIHYDROXY-6 (E) -HEPTENOIC ACID, INCLUDING ITS PHARMACEUTICALLY ACCEPTABLE SALTS
KR101157314B1 (ko) * 2009-06-05 2012-06-15 주식회사종근당 로수바스타틴의 신규한 제조방법, 이 제조에 유용한 중간체 화합물 및 그의 제조방법
WO2011083495A2 (en) * 2010-01-07 2011-07-14 Msn Laboratories Limited Process for the preparation of dihydroxy protected derivatives and novel intermediate compounds
EP2526099B1 (en) 2010-01-18 2016-03-30 MSN Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
US20120022102A1 (en) 2010-01-20 2012-01-26 Cadila Healthcare Limited Method for preparation of pitavastatin and its pharmaceutical acceptable salts thereof
JP2013519666A (ja) * 2010-02-23 2013-05-30 カディラ・ヘルスケア・リミテッド Ｈｍｇ−ｃｏａレダクターゼ阻害剤およびその調製のための方法
WO2011121595A1 (en) * 2010-04-01 2011-10-06 Neuland Laboratories Ltd. A process for the preparation of rosuvastatin calcium
WO2011132172A1 (en) 2010-04-23 2011-10-27 Ranbaxy Laboratories Limited NOVEL INTERMEDIATES FOR THE PREPARATION OF HMG-CoA REDUCTASE INHIBITORS
ITMI20110397A1 (it) * 2011-03-14 2012-09-15 Dipharma Francis Srl Procedimento per la preparazione di pitavastatina e analoghi
EP2383260A3 (en) * 2010-04-30 2011-12-28 Dipharma Francis S.r.l. Process for the preparation of statins
WO2012063254A1 (en) * 2010-11-12 2012-05-18 Hetero Research Foundation Novel polymorphs of pitavastatin calcium
HU230987B1 (hu) * 2010-11-29 2019-08-28 Egis Gyógyszergyár Nyrt. Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására
WO2012073256A1 (en) 2010-11-29 2012-06-07 Cadila Healthcare Limited Salts of rosuvastatin
HU229260B1 (en) * 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts
CN102174039B (zh) * 2011-03-10 2013-11-06 上海交通大学 高光学纯匹伐他汀钙关键中间体的制备方法
CN102816114B (zh) * 2011-06-09 2014-01-29 上海京新生物医药有限公司 一种HMG-CoA还原酶抑制剂的制备方法
CN103058925B (zh) * 2011-11-02 2015-09-02 石药集团中奇制药技术（石家庄）有限公司 一种匹伐他汀钙的制备方法
JP2013103884A (ja) * 2011-11-10 2013-05-30 Daito Kk ピタバスタチンカルシウム塩の工業的製造方法
EP2602249B1 (en) * 2011-12-06 2015-08-12 F.I.S. Fabbrica Italiana Sintetici S.p.A. Synthesis of rosuvastatin by means of co-crystals
CN103508946B (zh) * 2012-06-20 2016-06-29 徐州万邦金桥制药有限公司 匹伐他汀钙的制备方法
CN102898367B (zh) * 2012-11-15 2014-04-30 江苏阿尔法药业有限公司 一种匹伐他汀钙原料药中间体的制备方法
WO2014203045A1 (en) 2013-06-20 2014-12-24 Lupin Limited A novel, green and cost effective process for synthesis of tert-butyl (3r,5s)-6-oxo-3,5-dihydroxy-3,5-o-isopropylidene-hexanoate
WO2015037018A1 (en) * 2013-09-14 2015-03-19 Ind-Swift Laboratories Limited Process for the preparation of rosuvastatin via novel intermediates
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
WO2016080074A1 (ja) * 2014-11-17 2016-05-26 オリンパス株式会社 内視鏡リプロセッサ
KR20160126700A (ko) 2015-04-24 2016-11-02 미래파인켐 주식회사 스타틴의 중간체, 이의 제조방법 및 이를 이용한 로수바스타틴의 제조방법
CN106854201B (zh) * 2017-01-03 2019-12-06 浙江海洲制药有限公司 一种瑞舒伐他汀钙中间体的纯化方法
CN109574939B (zh) * 2017-09-28 2022-05-27 安徽省庆云医药股份有限公司 一种瑞舒伐他汀钠的制备方法
CN111788196A (zh) * 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
CN109053568A (zh) * 2018-08-29 2018-12-21 南京卓康医药科技有限公司 一种高纯度匹伐他汀钙新晶型及其制备方法
CN109651259B (zh) * 2018-12-29 2020-05-19 浙江永太科技股份有限公司 一种瑞舒伐他汀钙关键中间体的纯化方法
CN111518035A (zh) * 2020-06-18 2020-08-11 安徽鼎旺医药有限公司 一种瑞舒伐他汀叔丁胺盐及其制备方法
CN112592336A (zh) * 2021-01-28 2021-04-02 安徽美诺华药物化学有限公司 一种瑞舒伐他汀钙的高级中间体及其制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US573675A (en) * 1896-12-22 Fumigator
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
DE3741509A1 (de) 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
US5753675A (en) 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1995011898A1 (en) 1992-05-12 1995-05-04 Nissan Chemical Industries Ltd. Condensed pyridine type mevalonolactone intermediate and process for its production
JPH0641114A (ja) * 1992-05-25 1994-02-15 Nissan Chem Ind Ltd 新規メバロノラクトン類とその製法
GB9314159D0 (en) 1993-07-08 1993-08-18 Zeneca Ltd Chemical process
US5393893A (en) 1993-11-08 1995-02-28 Apotex, Inc. Process for producing simvastatin and analogs thereof
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
DE69813538T2 (de) 1997-01-28 2004-04-01 Plus Chemicals B.V. Verfahren zur herstellung von halbsynthetischen statinen vianeue zwischenprodukte
ATE392894T1 (de) 1997-08-28 2008-05-15 Novartis Pharma Gmbh Lymphozyten funktion antigen-1 antagonisten
NO991045L (no) 1998-03-05 1999-09-06 Synthon Bv FremgangsmÕte ved fremstilling av simvastatin og/eller dets derivater
AU746722C (en) 1998-07-23 2003-03-27 Nissan Chemical Industries Ltd. Process for the preparation of quinoline derivative and intermediate therefor
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US6627636B2 (en) 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
NZ524418A (en) 2000-07-27 2004-12-24 Plus Chemicals B Highly purified simvastatin compositions
JP4783998B2 (ja) 2001-05-15 2011-09-28 宇部興産株式会社 （３ｒ，５ｓ）−７−置換−３，５−ジヒドロキシヘプト−６−エン酸の製法
JP2004520445A (ja) 2001-05-18 2004-07-08 オーロビンド ファーマ リミテッド シンバスタチンを生成するためのラクトン化法
CN1656077A (zh) * 2001-06-06 2005-08-17 布里斯托尔-迈尔斯斯奎布公司 制备手性二醇砜和二羟基酸HMGCoA还原酶抑制剂的方法
US7304156B2 (en) 2001-07-13 2007-12-04 Astrazeneca Uk Limited Preparation of aminopyrimidine compounds
PL370407A1 (en) * 2001-08-16 2005-05-30 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
US6472542B1 (en) 2001-11-29 2002-10-29 Fermic S.A. De C.V. Method for alkylating the alpha carbon of the 2-methylbutyrate secondary chain of lovastatin
US6835838B2 (en) 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
DE60326819D1 (de) 2002-01-31 2009-05-07 Novartis Ag Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase
GB0204129D0 (en) 2002-02-21 2002-04-10 Novartis Ag Process for the manufacture of organic compounds
WO2003097614A2 (en) 2002-05-21 2003-11-27 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
CA2537271A1 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Process for preparation of rosuvastatin calcium
TWI343914B (en) 2003-10-03 2011-06-21 Nissan Chemical Ind Ltd Process for producing high purity 3,5-dihydroxy-6-heptenoic acid derivative
EP1678148A1 (en) 2003-10-22 2006-07-12 Ranbaxy Laboratories Limited Process for the preparation of amorphous rosuvastatin calcium
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2005054207A1 (en) 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
EP1709008A1 (en) * 2004-01-19 2006-10-11 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
US7161004B2 (en) 2004-06-21 2007-01-09 Dr. Reddy's Laboratories Limited Processes to produce intermediates for rosuvastatin
WO2006035277A2 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
CA2594692A1 (en) 2005-01-31 2006-08-03 Ciba Specialty Chemicals Holding Inc. Crystalline forms of rosuvastatin calcium salt
US20070037979A1 (en) 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
JP5146965B2 (ja) * 2005-06-24 2013-02-20 レツク・フアーマシユーテイカルズ・デー・デー 不純物を含まない非晶質ロスバスタチンカルシウムの調製方法
CZ299215B6 (cs) 2005-06-29 2008-05-21 Zentiva, A. S. Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny
CA2619236A1 (en) 2005-09-13 2007-09-07 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Process for preparing simvastatin and intermediates thereof
JP2008526897A (ja) 2005-10-03 2008-07-24 テバ ファーマシューティカル インダストリーズ リミティド ロスバスタチンのジアステレオマー精製
WO2007052309A2 (en) 2005-11-03 2007-05-10 Morepen Laboratories Limited Improved process for manufacturing statins
US20100274014A1 (en) 2006-01-30 2010-10-28 Cadila Healthcare Limited Process for manufacturing rosuvastatin potassium and crystalline and amorphous forms thereof
CN1821242B (zh) * 2006-02-16 2012-03-07 亚邦化工集团有限公司 制备二羟基酸HMG-CoA还原酶抑制剂的新方法
ES2564250T3 (es) 2006-05-03 2016-03-21 Msn Laboratories Private Limited Nuevo proceso para estatinas y sus sales farmacéuticamente aceptables de las mismas
WO2007132482A2 (en) 2006-05-17 2007-11-22 Manne Satyanarayana Reddy Novel process for the preparation of pitavastatin and its pharmaceutically acceptable salts
EP2086945B1 (en) 2006-10-09 2016-01-06 MSN Laboratories Private Limited Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
US20090054450A1 (en) * 2007-06-19 2009-02-26 Ironwood Pharmaceuticals, Inc. Compositions and methods of use for treating or preventing lipid related disorders
CN101386592B (zh) 2008-10-30 2010-08-18 上海交通大学 利用不对称氢化制备匹伐他汀钙原料药的方法

Also Published As

Publication number Publication date
EP2024341B1 (en) 2015-12-02
EP2024341A4 (en) 2013-05-01
US8455640B2 (en) 2013-06-04
ES2564250T3 (es) 2016-03-21
WO2007125547A3 (en) 2008-04-03
WO2007125547A2 (en) 2007-11-08
HUE027872T2 (en) 2016-11-28
WO2007125547A9 (en) 2007-12-21
EP2024341A2 (en) 2009-02-18
US20090275752A1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
SI2024341T1 (sl) Novi postopek za statine in njihove farmacevtsko sprejemljive soli
EP2086945A4 (en) NOVEL PROCESS FOR THE PRODUCTION OF STATINES AND THEIR PHARMACEUTICAL ACCEPTIC SALTS
AP3004A (en) Process and intermediates for preparing integrase inhibitors
IL198851A0 (en) Methods for treating hypercholesterolemia
GB0608820D0 (en) Pharmaceutical compounds
IL181607A0 (en) Novel process for preparing montelukast and salts thereof
IL193236A0 (en) Novel pyrone-indole derivatives and process for their preparation
IL198117A0 (en) Process for preparing indol-5-oxy-quinazoline derivatives and intermediates
EP2035410A4 (en) PROCESS FOR PREPARING ESOMEPRAZOLE AND ITS SALTS
GB0606234D0 (en) Pharmaceutically acceptable salts and polymorphic forms
GB0719248D0 (en) Compounds and methods for pharmaceutical use
ZA200902575B (en) Process for the synthesis of clopidogrel and new forms of pharmaceutically acceptable salts thereof
GB0608176D0 (en) Pharmaceutical Compounds
GB0608184D0 (en) Pharmaceutical compounds
GB0608264D0 (en) Pharmaceutical compounds
GB0608175D0 (en) Pharmaceutical Compounds
GB0605344D0 (en) Pharmaceutically acceptable salts and polymorphic forms
IL194873A0 (en) Methods for reducing 7/9-nitrotetracycline derivatives
ZA200809008B (en) 2-alkenyl-3-aminothipene derivative and process for producing thereof
GB0622892D0 (en) Pharmaceutical compounds
GB0609465D0 (en) Pharmaceutically acceptable salts and polymorphic forms
GB0611349D0 (en) Pharmaceutical excipient
GB0618135D0 (en) Novel pharmaceutical
GB0608178D0 (en) Pharmaceutical compounds
GB0604111D0 (en) Pharmaceutical compounds